As a plan to follow a more focused strategy, consumer giant Johnsons and Johnsons (J&J) has decided to spin off its Consumer Health business as a independant public traded company by end 2022. A separate company will house its Pharma and Medical Devices business. The split will allow J&J to not only target its personal care brands like Neutrogena, Aveeno etc with more focus, there will also be a devoted R&D investment in this area. J&J aims to rule the business world by becoming ‘two global leaders’ after the division.